Analytical Data
-
基因名
Staphylococcus aureus
- Application
-
生物活性
Measured by its binding ability in a functional ELISA. Immobilized Protein G at 2μg/mL (100μL/well) can bind Biotinylated Human IgG1. The ED50 for this effect is 0.1099 μg/mL. Measured by its binding ability in a functional ELISA. Immobilized Protein G at 2 μg/mL (100 μL/well) can bind Biotinylated Human IgG1. The ED50 for this effect is 0.1099 μg/mL.
-
别名
Immunoglobulin G-binding protein G; spg; IgG-binding protein G
-
种属
Staphylococcus aureus
-
表达系统
E. coli
-
标签
C-6*His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
分子量
27 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Staphylococcus aureus is a significant pathogenic bacterium responsible for a wide range of infections in humans, ranging from mild skin infections to severe conditions like pneumonia and sepsis. The emergence of antibiotic-resistant strains, particularly Methicillin-resistant Staphylococcus aureus (MRSA), has heightened the need for novel therapeutic strategies and preventive measures. Research on recombinant proteins derived from Staphylococcus aureus focuses on the development of vaccines and targeted therapies. By utilizing recombinant DNA technology, scientists can produce specific antigens that elicit strong immune responses, potentially leading to effective vaccines that can protect against infections. Additionally, these proteins can serve as valuable tools in understanding virulence mechanisms and host-pathogen interactions. The investigation of recombinant proteins also aids in the identification of biomarkers for early diagnosis and monitoring of infections. With the increasing global burden of antibiotic resistance, the ongoing research in this area is crucial for enhancing public health protection and developing innovative solutions to combat Staphylococcus aureus-related diseases.
